Product
Placebo + Paclitaxel
Name
Placebo + Paclitaxel
1 clinical trial
1 indication
Indication
Gastric AdenocarcinomaClinical trial
Nimotuzumab Combined With Paclitaxel as Second-line Treatment for Recurrent Metastatic Gastric or Esophagogastric Junction Adenocarcinoma With EGFR Over-expression: A Randomized, Double-blind, Placebo-controlled Phase III Clinical TrialStatus: Not yet recruiting, Estimated PCD: 2026-03-01